

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8040994

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PROMORE PHARMA AB	07/04/2023
RECEIVING PARTY DATA	
Name:	PERGASUS AB
Street Address:	FOGDEVRETEN 2
City:	SOLNA
State/Country:	SWEDEN
Postal Code:	171 65
PROPERTY NUMBERS Total: 3	
Property Type	Number
Patent Number:	10226508
Patent Number:	10709760
Patent Number:	11191810
CORRESPONDENCE DATA	
Fax Number:	(617)607-9200
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6174496500
Email:	ptedesco@mccarter.com
Correspondent Name:	MCCARTER & ENGLISH LLP
Address Line 1:	265 FRANKLIN STREET
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	125048-00202
NAME OF SUBMITTER:	STEVEN G. DAVIS
SIGNATURE:	/Steven G. Davis/
DATE SIGNED:	07/05/2023
Total Attachments: 1	
source=Patent Assignment Deed (125048-00204)#page1.tif	

PATENT ASSIGNMENT

Promore Pharma AB (Assignor), a pharmaceutical company registered in Sweden with the company registration no. 556639-6809, and office address at Fogdevreten 2, SE-171 65 Solna, SWEDEN, is the owner of the right, title and interest in and to the following patents in the United States:

- US 10,226,508;
- US 10,709,760; and
- US 11,191,810.

Pergasus AB (Assignee), is a pharmaceutical company registered in Sweden with the company registration no. 559349-7695, and office address at Fogdevreten 2, SE-171 65 Solna, SWEDEN.


Pergasus AB is now desirous of acquiring full and complete patent ownership, title and interest in and to the above listed patents in the United States, and Promore Pharma AB hereby assigns the right, title and interest in and to the herein listed patents in the United States, all priority rights claimed, any patent term extensions, as well as the rights to file law suits for patent infringements and defend the patents.

Swedish law shall apply to this Assignment. The courts of Stockholm, Sweden, shall have exclusive jurisdiction for any dispute arising from or in connection to this Assignment agreement.

The present assignment is consented for good valuable consideration, the receipt and sufficiency of which is hereby acknowledged.

Assignor:


Place and date: Solna, 4 July 2023



Jonas Ekblom, CEO and President
Promore Pharma AB

Assignee:

Place and date: Solna, 4 July 2023



Jonas Ekblom, CEO and President
Pergasus AB